Retatrutide is the compound most researchers are watching right now, and it is also the one most often misunderstood. It is not another GLP-1. It is the first triple agonist to reach late-stage trials, and that changes what the research protocols look like.
The masterclass below covers the mechanism, the trial data and the practical protocol considerations in one sitting. Watch it first, then use the reconstitution maths underneath to work out what that means for a 30mg vial.
Third-party educational video, shared for reference. LA LAB did not produce it and is not affiliated with the channel.
Why "triple agonist" matters
Semaglutide acts on one receptor. Tirzepatide acts on two. Retatrutide acts on three — GLP-1, GIP and glucagon — and it is the third one that makes it different.
GLP-1 and GIP activity work largely on the intake side: appetite signalling, gastric emptying and insulin response. Glucagon receptor agonism works on the other side of the equation, on energy expenditure and hepatic fat mobilisation. Researchers are interested in Retatrutide precisely because it engages both directions at once rather than only suppressing intake.
What the trial data showed
The Phase 2 results published in the New England Journal of Medicine reported mean body-weight reductions substantially beyond those seen with dual agonists over a 48-week period, with a clear dose-response relationship. Tolerability findings mirrored the wider incretin class — gastrointestinal effects concentrated in the titration phase and easing as the dose stabilised.
Retatrutide has not been approved by SAHPRA, the FDA or any other regulator. It remains an investigational compound.
Every incretin protocol in the literature steps the dose up gradually. This is not caution for its own sake — the gastrointestinal effects are dose-dependent and front-loaded. Starting high does not accelerate anything; it simply makes the first fortnight unpleasant enough that most people stop.
The reconstitution maths — 30mg vial
LA LAB supplies Retatrutide as a 30mg vial with 3ml bacteriostatic water, giving 10mg/ml. On a U-100 insulin syringe that is 100 units per millilitre, so one unit carries 0.1mg. On a reusable pen, one click equals one unit.
| Dose | Syringe units | Pen clicks | Doses per vial |
|---|---|---|---|
| 2.5 mg | 25 units | 25 clicks | 12 |
| 5 mg | 50 units | 50 clicks | 6 |
| 7.5 mg | 75 units | 75 clicks | 4 |
| 10 mg | 100 units | 80 + 20 (turn twice) | 3 |
A standard reusable pen tops out at 80 clicks per turn, which is why a 10mg draw is dialled as 80 then 20. Reconstitute by running the water slowly down the inside wall of the vial, swirl gently, never shake, and refrigerate at 2–8 °C. Use within 30 days once reconstituted.
Where people get it wrong
Escalating too quickly. The dose-response curve is real, but so is the tolerability curve. Most protocols hold each step for several weeks before moving up.
Ignoring protein intake. Rapid weight reduction without adequate protein shifts the composition of what is lost. This is the single most common complaint in the wider incretin literature and it is entirely avoidable.
Shaking the vial. Peptides are fragile. Agitation degrades them. Swirl, always.
Related reading
If you are comparing compounds, our microdosing Tirzepatide and Retatrutide article covers the lower-dose protocols, and the reconstitution calculator will work out units for any vial size and dose you enter.